In Vitro Diagnostics and Theranostics: World Market Analysis 2010-2025

Our new report examines the commercial prospects for in vitro diagnostics (IVD) in the global healthcare market. Those technological solutions are playing an important role in clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Molecular diagnostic technologies are leading healthcare towards the goal of personalised medicine, to the benefit of healthcare stakeholders. Molecular diagnostic tests receive support from pharmaceutical regulators, such as the FDA.

We believe that some of the greatest opportunities ever available for diagnostics companies are present, with important sales, licensing and partnership developments to occur from 2010 onwards. Pharmaceutical companies also stand to gain, through the benefits of molecular diagnostics. We predict increasing revenues in the years ahead. Do you want to know where the most-promising opportunities will occur? How will companies adapt to the opportunities and challenges? In Vitro Diagnostics and Theranostics: World Market Analysis 2010-2025 answers those and many other questions, providing the information that you require.

Our new report also covers theranostics, a fusion of drug therapy and diagnostics to optimise efficacy and safety, as well as streamline drug development. Combining a drug with a diagnostic test is also known as companion diagnostics, integrated medicine, pharmacodiagnostics and Dx/Rx partnering. This emerging field is generating strong interest from the healthcare industry and regulatory bodies, with the associated market expanding as the importance of theranostics is recognised, especially in cancer treatment.

Detailed analysis of the in vitro diagnostics industry and market

In Vitro Diagnostics and Theranostics: World Market Analysis 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of emerging technologies and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 110 tables and figures included, as well as four interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.


Report Highlights
Companies Listed
23andMe
Abbott Laboratories
AmeriPath
Axis-Shield
Beckman Coulter
Becton, Dickinson & Company
BIOTEC Laboratories
bioTheranostics
Cellestis
Center for Disease Control and Prevention (CDC)
Clinical Data
Complete Genomics
Dade Behring
Dianon Systems
Duke University
Dynacare Laboratories
Enterix
EntroGen
Esoterix
European Diagnostic Manufacturers Association (EDMA)
European Medicines Evaluation Agency (EMEA)
Focus Diagnostics
Food and Drug Administration (FDA)
Genetics & Public Policy Center
HemoCue
Hologic
Home Access Health
Laboratory Corporation of America
Litholink Corporation
Modern Health Systems
Monogram Bioscience
Myriad Genetics
National Genetics Institute
National Health Service (UK NHS)
Navigenics
OraSure Technologies
Oxford Immunotec
ParagonDx
Pathway Genomics
Pfizer
Prometheus
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Siemens
US LABS
Vermillion Diagnostics
ViroMed Laboratories
Walgreens
Warner-Chilcott
World Health Organization (WHO)
[Fade out table of contents]

Table 2.1 Criticisms of the CLIA System
Table 3.1 Global IVD Market: Revenues by EDMA Category, 2009
Table 3.2 The Global IVD Market: Revenue Forecast, 2010-2025
Table 3.3 Global IVD Market: Revenue Forecast by Submarket, 2010-2015
Table 3.4 Clinical Chemistry IVD Applications, 2010
Table 3.5 Clinical Chemistry IVD Market: Revenue Forecast, 2010-2025
Table 3.6 Immunochemistry IVD Applications, 2010
Table 3.7 Immunochemistry IVD Market: Revenue Forecast, 2010-2025
Table 3.8 Haematology IVD Applications, 2010
Table 3.9 Haematology IVD Market: Revenue Forecast, 2010-2025
Table 3.10 Microbiological Culture Applications, 2010
Table 3.11 Microbiology Culture IVD Market: Revenue Forecast, 2010-2025
Table 3.12 Infectious Immunology Applications, 2010
Table 3.13 Infectious Immunology Market: Revenue Forecast, 2010-2025
Table 3.14 Genetic Testing Applications, 2010
Table 3.15 Genetic Testing Market: Revenue Forecast, 2010-2025
Table 3.16 POCT and Laboratory Testing Market Shares by Revenue, 2009
Table 3.17 The Point-of-Care IVD Market: Revenue Forecast, 2010-2025
Table 3.18 The Laboratory Testing Market: Revenue Forecast, 2010-2025
Table 3.19 The Laboratory Testing and POCT Markets: Revenue Forecasts, 2010-2025
Table 4.1 Leading IVD Markets by Revenue, 2009
Table 4.2 Nine Leading National IVD Markets: Revenue Forecasts, 2010-2025
Table 4.3 The US IVD Market: Revenue Forecast, 2010-2025
Table 4.4 The US IVD Market: Revenue Forecast, 2010-2025
Table 4.5 Healthcare Budgets and IVD Spending of Top Five European Countries, 2009
Table 4.6 The German IVD Market: Revenue Forecast, 2010-2025
Table 4.7 The French IVD Market: Revenue Forecast, 2010-2025
Table 4.8 The Italian IVD Market: Revenue Forecast, 2010-2025
Table 4.9 The Spanish IVD Market: Revenue Forecast, 2010-2025
Table 4.10 The UK IVD Market: Revenue Forecast, 2010-2025
Table 4.11 The Chinese IVD Market: Revenue Forecast, 2010-2025
Table 4.12 The Indian IVD Market: Revenue Forecast, 2010-2025
Table 4.13 Global IVD Market by Regional Revenue Shares, 2009
Table 5.1 Top Five IVD Manufacturers by Revenue, 2009
Table 5.2 Roche: Diagnostic Business Revenues, 2009
Table 5.3 Roche: Bestselling IVD Products, 2009
Table 5.4 Siemens: Revenues by Business Segment, 2009
Table 5.5 Abbott: Revenues by Business Segment, 2009
Table 5.6 Beckman Coulter: Revenues by Business Segment, 2009
Table 5.7 BD: Revenues by Business Segment, 2009
Table 5.8 Quest: Revenues by Business Segment, 2009
Table 5.9 LabCorp: Revenues by Business Segment, 2009
Table 5.10 Conditions Tested for by 23andMe, 2010
Table 6.1 Key Disease Areas: Revenues from IVDs, 2009
Table 6.2 Diabetes Market by Marker, 2009
Table 6.3 POCT by Application, 2009
Table 6.4 Cancer IVD Revenues, 2009
Table 6.5 Theranostics for Oncology, 2010
Table 6.6 Infectious Disease IVD Market by Technology, 2009
Table 6.7 Infectious Disease IVD Market: Revenues by Disease, 2009
Table 6.8 HIV IVD Market: Revenues by Application, 2009
Table 6.9 TB Diagnostics by Revenue, 2009
Table 6.10 Male and Female Fertility Markers, 2010
Table 6.11 Detection Windows for Various DoA Tests, 2010
Table 6.12 Cardiovascular IVD Market: Revenue by Application, 2009
Table 6.13 Common Cardiac Markers, 2010
Table 6.14 Cardiac Marker IVD Market: Revenues by Test Type, 2009
Table 7.1 Comparison of Traditional and Personalised Medicine, 2010
Table 7.2 Average Response Rates to Treatment for Various Diseases, 2010
Table 7.3 Drugs Metabolised by CYP450: 2C19 and 2D6, 2010
Table 7.4 The Falling Cost of Sequencing Complete Human Genome
Table 7.5 Diagnostics and Theranostics: Revenue Forecasts, 2010-2025
Table 7.6 Genetic IVDs: Theranostics and Other Tests Revenue Forecasts, 2010-2025
Table 8.1 SWOT Analysis of IVD Market, 2010-2025

Figure 3.1 Global IVD Market: Revenues by EDMA Category, 2009
Figure 3.2 The Global IVD Market: Revenue Forecast, 2010-2025
Figure 3.3 Global IVD Market: Revenue Forecast by Submarket, 2010-2015
Figure 3.4 Clinical Chemistry IVD Market: Revenue Forecast, 2010-2025
Figure 3.5 Immunochemistry IVD Market: Revenue Forecast, 2010-2025
Figure 3.6 Haematology IVD Market: Revenue Forecast, 2010-2025
Figure 3.7 Microbiology Culture IVD Market: Revenue Forecast, 2010-2025
Figure 3.8 Infectious Immunology Market: Revenue Forecast, 2010-2025
Figure 3.9 Genetic Testing Market: Revenue Forecast, 2010-2025
Figure 3.10 POCT and Laboratory Testing Market Shares, 2009
Figure 3.11 The Point-of-Care IVD Market: Revenue Forecast, 2010-2025
Figure 3.12 The Laboratory Testing Market: Revenue Forecast, 2010-2025
Figure 3.13 The Laboratory Testing and POCT Markets: Revenue Forecasts, 2010-2025
Figure 4.1 Leading National IVD Markets by Share of Worldwide Revenue, 2009
Figure 4.2 Leading National IVD Markets (Upper Tier): Revenue Forecasts, 2010-2025
Figure 4.3 Leading National IVD Markets (Lower Tier): Revenue Forecast, 2010-2025
Figure 4.4 The US IVD Market: Revenue Forecast, 2010-2025
Figure 4.5 The Japanese IVD Market: Revenue Forecast, 2010-2025
Figure 4.6 The German IVD Market: Revenue Forecast, 2010-2025
Figure 4.7 The French IVD Market: Revenue Forecast, 2010-2025
Figure 4.8 The Italian IVD Market: Revenue Forecast, 2010-2025
Figure 4.9 The Spanish IVD Market: Revenue Forecast, 2010-2025
Figure 4.10 The UK IVD Market: Revenue Forecast, 2010-2025
Figure 4.11 The Chinese IVD Market: Revenue Forecast, 2010-2025
Figure 4.12 The Indian IVD Market: Revenue Forecast, 2010-2025
Figure 4.13 Market Shares of Leading National Markets, 2010
Figure 4.14 Market Shares of Leading National Markets, 2015
Figure 4.15 Market Shares of Leading National Markets, 2020
Figure 4.16 Market Shares of Leading National Markets, 2025
Figure 4.17 Global IVD Market by Region, 2009
Figure 5.1 Market Shares of the Top Five IVD Manufacturers, 2009
Figure 5.2 Roche: Diagnostic Business by Revenue, 2009
Figure 5.3 Roche: Bestselling IVD Products, 2009
Figure 5.4 Siemens Healthcare: Revenues by Division, 2009
Figure 5.5 Siemens AG: Revenues by Business Segment, 2009
Figure 5.6 Abbott: Revenues by Business Segment, 2009
Figure 5.7 Beckman Coulter: Revenues by Business Segment, 2009
Figure 5.8 BD: Revenues by Business Segment, 2009
Figure 5.9 Quest: Revenues by Business Segment, 2009
Figure 5.10 LabCorp: Revenues by Business Segment, 2009
Figure 6.1 Key Disease Areas: Revenues from IVD Applications, 2009
Figure 6.2 Diabetes Market by Marker, 2009
Figure 6.3 POCT Market by Application, 2009
Figure 6.4 Cancer IVD Revenues, 2009
Figure 6.5 Infectious Disease IVD Market: Revenues by Technology, 2009
Figure 6.6 Infectious Disease IVD Market: Revenues by Disease, 2009
Figure 6.7 HIV IVD Market: Market Shares by Application, 2009
Figure 6.8 TB Diagnostics by Revenue, 2009
Figure 6.9 Cardiovascular IVD: Market Shares by Application, 2009
Figure 6.10 Cardiac Marker IVDs: Market Shares by Test Type, 2009
Figure 7.1 Average Response Rates to Treatment for Various Diseases, 2010
Figure 7.2 The Falling Cost of Sequencing the Whole Human Genome
Figure 7.3 Theranostic IVD Market: Revenue Forecast, 2010-2025
Figure 7.4 Global IVD Market: Theranostic and Diagnostic Market Shares, 2010-2025
Figure 7.5 Genetic IVD Applications: Revenue Forecasts for Theranostics and Other Tests, 2010-2025
[Fade out list of tables / figures]